Thus, cell cycle kinases and checkpoints are suitable therapeutic targets for cancer.[41,42] Besides, ssGSEA showed that the high-risk and low-risk groups differed significantly in terms of the infiltrating immune cell populations, especially CD4 + T cells, DCs, MDSCs, Tregs, Th2 cells, and Th17 cells. The gene discussed is CD4; the disease is cancer.